L'Oréal et Symatese ont annoncé la signature de nouveaux accords de recherche et développement à long terme dans le domaine des biomatériaux, afin de renforcer et d'élargir leur partenariat stratégique existant.
Ensemble, les entreprises aspirent à combiner leurs expertises respectives pour explorer de nouvelles perspectives scientifiques dans le domaine des biomatériaux conçus pour la physiologie des tissus humains, y compris la peau, notamment à des fins de régénération.
This research partnership builds on the success of the close collaboration between the two companies during the past 20 years. Episkin S.A., a subsidiary of the L’Oréal group, the world leader in the production of reconstructed human tissues, has benefitted from the know-how developed historically with Symatese, a company recognized for the quality of its technological platforms to extract and transform biopolymers for multiple therapeutic indications. These reconstructed tissues have become a reference in the field of biomedical research, and a key tool for a number of industries as reliable non-animal evaluation methods for ingredient and product testing.
“Following our long-term collaboration with Symatese, we are very pleased to enter into this new phase of our scientific partnership, which supports the exploration of new horizons for research and innovation, with the objective to offer men and women around the world even more superior product performance with our beauty and skincare offering. Through this collaboration and thanks to Symatese’s expertise in the therapeutic field, L’Oréal will benefit from an internationally recognized cutting-edge know-how in the field of biomaterials,” said Barbara Lavernos, Deputy CEO in charge of Research, Innovation and Technology, L’Oréal Group.
Jean-Paul Gérardin, CEO of Symatese Group, said: “We are delighted to establish this new partnership with L’Oréal, whose extensive expertise in the field of skin physiology, clinical performance markers and alternative assessment methods perfectly matches our knowledge in the design and industrialization of biomaterials. We expect great scientific advances and innovative products from this collaboration.”
+33 (0)1 47 56 70 00
Actionnaires individuels et marché
+33 (0)1 47 56 72 06
Analystes financiers et institutionnels
+33 (0)1 47 56 86 82
+33 (0)6 79 92 99 39
+33 (0)6 75 54 38 15
+33 (0)6 29 44 83 09